Durect Stock Sees Surge with Bausch Health Merger and FDA Designations

Major shareholder Scott Asen has purchased 5,917 shares of Durect (DRRX) valued at $11,301. The company's Q2 earnings report showed a decrease in total revenues to $447,000 and a net loss of $2.3 million. Durect is undergoing a merger with Bausch Health, which may impact operations and stakeholder interests. Despite financial challenges, the merger offers strategic benefits, and the company's lead drug candidate has received FDA designations. Durect's stock has increased 270% due to merger news and cost management efforts.

Bausch Health Companies Inc. (NYSE: BHC) has extended its tender offer to acquire all outstanding shares of Durect Corporation (NASDAQ: DRRX) until September 10, 2025 [1]. The offer, initially scheduled to expire on September 9, 2025, now provides shareholders additional time to tender their shares. The extended offer allows BHC to acquire shares at $1.75 each, with a potential for additional milestone payments totaling up to $350 million [1].

The merger, if successful, could bring strategic benefits to Durect, despite the company's recent financial challenges. Durect reported a decrease in total revenues to $447,000 and a net loss of $2.3 million for the second quarter [2]. However, the company's lead drug candidate, larsucosterol, has received FDA designations, including Fast Track and Breakthrough Therapy designations, for the potential treatment of acute organ injury [1].

Major shareholder Scott Asen recently purchased 5,917 shares of Durect valued at $11,301, reflecting the market's optimism surrounding the merger and cost management efforts [2]. The merger with Bausch Health, a global diversified pharmaceutical company, may impact Durect's operations and stakeholder interests. Despite the financial setbacks, Durect's stock has increased by 270% since the merger news was announced [2].

The tender offer materials, including the Offer to Purchase and related documents, are available on the SEC's website at www.sec.gov [1]. Investors and shareholders are encouraged to review these documents carefully before making any decisions regarding the offer.

References:
[1] https://www.biospace.com/press-releases/bausch-health-announces-extension-of-durect-corporation-tender-offer-to-september-10-2025
[2] https://www.durect.com/investors/